LiquidSEQ™

LIQSEQ or 14308

10 mL whole blood collected in each of two separate Streck cell-free DNA blood collection tubes

10 mL

This test requires two Streck tubes. Blood will be collected in office via Quest-LiquidSEQ Gen Kit. Specimens may be shipped separately and at different times. Do not hold blood specimen due to short stability. Do not reject.

Blood collection using a straight needle is preferred. Use kit only. All tubes must be filled completely. Gently invert tube at least 8 times immediately after draw.

Room temperature

Room temperature: 7 days
Refrigerated: Unacceptable
Frozen: Unacceptable

Do not reject, send to laboratory for testing assessment

Sun, Tues, Thurs

7-10 days

**This test is not available for New York and Wyoming patient testing**

See Laboratory Report

The 523-gene comprehensive genomic profiling panel is intended to help oncologists deliver precision medicine by providing personalized genomic analysis of a patient’s blood. This comprehensive panel offers the opportunity for a broader scope of genomic information compared to single gene tests or smaller panels and an alternative specimen type for comprehensive genomic profiling of a patient’s solid tumor. For example, it may be useful for patients with limited or ill-defined treatment options and for those considering clinical trials in the event tumor tissue is not available or insufficient for tissue-based testing. This panel uses next-generation sequencing to detect mutations present in circulating tumor DNA (ctDNA) extracted from a solid tumor patient’s blood plasma. The test is designed to detect single nucleotide variants (SNVs) and small insertions/deletions, as well as whole-gene copy number alterations and translocations in a select group of genes. Microsatellite instability (MSI) and tumor mutation burden (TMB) are also evaluated.